Bristol-Myers Squibb announced Thursday that it’s going to acquire another drugmaker, Celgene. The deal is worth about $74 billion. The combined company will have nine products with sales of more than a billion dollars a year, including some blockbuster cancer drugs. The merger is a sign that Big Pharma is betting big on cancer medications.
Click the audio player above to hear the full story.
Marketplace is on a mission.
We believe Main Street matters as much as Wall Street, economic news is made relevant and real through human stories, and a touch of humor helps enliven topics you might typically find…well, dull.
Through the signature style that only Marketplace can deliver, we’re on a mission to raise the economic intelligence of the country—but we don’t do it alone. We count on listeners and readers like you to keep this public service free and accessible to all. Will you become a partner in our mission today?